Home ›
Sarcoma Trials ›
NCT05797662
A Study of Propranolol to Treat Kaposi Sarcoma
A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.
Trial Details
NCT ID NCT05797662
Phase PHASE2
Sponsor AIDS Malignancy Consortium
Status RECRUITING
Cancer Type Sarcoma
Interventions
Locations (sample) Buenos Aires, Argentina|-34.61315,-58.37723 Rio de Janeiro, Brazil|-22.90642,-43.18223 Salvador, Brazil|-12.97563,-38.49096 Mexico City, Mexico|19.42847,-99.12766 Kampala, Uganda|0.31628,32.58219
Key Eligibility Criteria
Pediatric (\< 18 years) and adult (≥ 18 years) participants with biopsy-proven and measurable Kaposi Sarcoma (KS) as defined in the KS Manual of Pr… No urgent clinical indication for immediate cytotoxic chemotherapy. Participants who have received cytotoxic chemotherapy \> 4 weeks prior to scree… \< 18 years: 1A (Mild): disease limited to skin, flat oral mucosal lesions, and/or flesh colored subcutaneous nodules, total \<10 lesions.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →